Log in

Relevant bibliographies by topics / Platinum group. Antineoplastic agents

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Platinum group. Antineoplastic agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Platinum group. Antineoplastic agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Platinum group. Antineoplastic agents"

1

Odularu, Ayodele T., Peter A. Ajibade, Johannes Z. Mbese, and Opeoluwa O. Oyedeji. "Developments in Platinum-Group Metals as Dual Antibacterial and Anticancer Agents." Journal of Chemistry 2019 (November 6, 2019): 1–18. http://dx.doi.org/10.1155/2019/5459461.

Full text

Abstract:

Platinum-group (PG) complexes have been used as antibacterial and anticancer agents since the discovery of cisplatin. The science world still requires improvement on these complexes because of multidrug and antineoplastic resistances. This review observes discoverers and history of these platinum-group metals (PGMs), as well as their beneficial applications. The focus of this study was biological applications of PGMs in relation to human health. Sandwich and half-sandwich PGM coordination compounds and their metal nanoparticles give improved results for biological activities by enhancing efficient delivery of both antibacterial and anticancer drugs, as well as luminescent bioimaging (biomarkers) for biological identifications.

APA, Harvard, Vancouver, ISO, and other styles

2

César, Bruno Nogueira, and Marcelino de Souza Durão Júnior. "Acute kidney injury in cancer patients." Revista da Associação Médica Brasileira 66, suppl 1 (2020): s25—s30. http://dx.doi.org/10.1590/1806-9282.66.s1.25.

Full text

Abstract:

SUMMARY The increasing prevalence of neoplasias is associated with new clinical challenges, one of which is acute kidney injury (AKI). In addition to possibly constituting a clinical emergency, kidney failure significantly interferes with the choice and continuation of antineoplastic therapy, with prognostic implications in cancer patients. Some types of neoplasia are more susceptible to AKI, such as multiple myeloma and renal carcinoma. In cancer patients, AKI can be divided into pre-renal, renal (intrinsic), and post-renal. Conventional platinum-based chemotherapy and new targeted therapy agents against cancer are examples of drugs that cause an intrinsic renal lesion in this group of patients. This topic is of great importance to the daily practice of nephrologists and even constitutes a subspecialty in the field, the onco-nephrology.

APA, Harvard, Vancouver, ISO, and other styles

3

Azab, Belal, Anood Alassaf, Abdulrahman Abu-Humdan, Zain Dardas, Hashem Almousa, Mohammad Alsalem, Omar Khabour, Hana Hammad, Tareq Saleh, and Abdalla Awidi. "Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study." Interdisciplinary Toxicology 12, no. 2 (October 1, 2019): 93–97. http://dx.doi.org/10.2478/intox-2019-0011.

Full text

Abstract:

Abstract Cisplatin and carboplatin are integral parts of many antineoplastic management regimens. Both platinum analogues are potent DNA alkylating agents that robustly induce genomic instability and promote apoptosis in tumor cells. Although the mechanism of action of both drugs is similar, cisplatin appears to be more cytotoxic. In this study, the genotoxic potential of cisplatin and carboplatin was compared using chromosomal aberrations (CAs) and sister-chromatid exchange (SCE) assays in cultured human lymphocytes. Results showed that cisplatin and carboplatin induced a significant increase in CAs and SCEs compared to the control group (p<0.01). Levels of induced CAs were similar in both drugs; however, the magnitude of SCEs induced by cisplatin was significantly higher than that induced by carboplatin (p<0.01). With respect to the mitotic and proliferative indices, both cisplatin and carboplatin significantly decreased mitotic index (p<0.01) without affecting the proliferative index (p>0.05). In conclusion, cisplatin was found to be more genotoxic than carboplatin in the SCE assay in cultured human lymphocytes, and that might explain the higher cytotoxicity of cisplatin.

APA, Harvard, Vancouver, ISO, and other styles

4

Li, Lu, Sheng Nie, Chen Ren, Yanqin Li, and Dehua Wu. "The incidence, risk factors and outcomes of chemotherapy related acute kidney injury in China." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e24161-e24161. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e24161.

Full text

Abstract:

e24161 Background: Nephrotoxicity of chemotherapeutic agents remains a significant complication limiting the efficacy of the treatment. However, comprehensive data on the epidemiology and outcomes of chemotherapy related acute kidney Injury in China is lacking. Methods: We conducted a nationwide cohort study of hospitalized patients from 25 general and children’s hospitals in China during 2013-2015. Patient-level data were obtained from the electronic hospitalization information system, prescription database and laboratory databases of all cancer patients who received chemotherapy and had at least two serum creatinine tests within any 7-day window during the hospitalization. AKI was defined and staged according to Kidney Disease Improving Global Outcomes criteria. The incidence of AKI in patients with various type of cancer and chemotherapeutic agents was examined. The outcomes of AKI, including in-hospital mortality, death after discharge, kidney recovery, and length of stay, were also assessed. Results: A total of 23,232 cancer patients, including 3,120 children ( < 18 years old), 16,310 adult (19-65 years old) and 3,802 elderly patients ( > 65 years old), were analyzed. Platinum compounds and pyrimidine analogues were the most common used chemotherapy agents for cancer patients. The overall incidence of AKI was 4.9%. Patients with urinary system malignancy (12.3%), hematological malignancy (10.2%) and nerve motor system malignancy (4.1%) have the highest incidence of HA-AKI. The top three types of chemotherapy drugs with the highest incidence of AKI were Purine analogues (30.1%), folic acid analogues (15.3%) and combinations of antineoplastic agents (14.1%). The nephrotoxicity of chemotherapy drugs was different among age groups. AKI is associated with a higher risk of in-hospital mortality and death after discharge. Conclusions: The risk of AKI in cancer patients varied in different age group, type of cancer and chemotherapeutic agents.

APA, Harvard, Vancouver, ISO, and other styles

5

Bakalova, Adriana G., Rossen T. Buyukliev, Rositsa P. Nikolova, Boris L. Shivachev, Rositsa A. Mihaylova, and Spiro M. Konstantinov. "Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin." Anti-Cancer Agents in Medicinal Chemistry 19, no. 10 (October 24, 2019): 1243–52. http://dx.doi.org/10.2174/1871520619666190214103345.

Full text

Abstract:

Background: The accidental discovery of Cisplatin’s growth-inhibiting properties a few decades ago led to the resurgence of interest in metal-based chemotherapeutics. A number of well-discussed factors such as severe systemic toxicity and unfavourable physicochemical properties further limit the clinical application of the platinating agents. Great efforts have been undertaken in the development of alternative platinum derivatives with an extended antitumor spectrum and amended toxicity profile as compared to the reference drug cisplatin. The rational design of conventional platinum analogues and the re-evaluation of the empirically derived “structure- activity” relationships allowed for the synthesis of platinum complexes with great diversity in structural characteristics, biochemical stability and antitumor properties. Methods: The new compounds have been studied by elemental analyses, IR, NMR and mass spectral analyses. The structures of the organic compound and one of the new mixed/ammine Pt(II) complexes were studied by X-ray diffraction analysis. The cytotoxic effects of the compounds were studied vs. the referent antineoplastic agent cisplatin against four human tumour cell lines using the standard MTT-dye reduction assay for cell viability. The most promising complex 3 was investigated for acute toxicity in male and female H-albino-mice models. Results: A new organic compound (5-methyl-5-(2-thiomethyl)ethyl hydantoin) L bearing both S- and Ncoordinating sites and three novel platinum complexes, 1, 2 and 3 were synthesized and studied. Spectral and structural characterization concluded monodentate S-driven coordination of the ligand L to the metal center in complexes 1 and 2, whereas the same was acted as a bidentate N,S-chelator in complex 3. Ligand L crystallizes in the tetragonal space group I41/a (No 88) with one molecule per asymmetric unit. While complex 3 crystallizes in the monoclinic space group P21/c (No 14) with one molecule per asymmetric unit. In the same complex 3, the platinum ion coordinates an L ligand, a chloride ion and an ammonia molecule. In the in vitro experiments, the tested L and complexes 1 and 2 exhibited negligible cytotoxic activity in all tumor models. Accordingly, complex 3 is twice as potent as cisplatin in the HT-29 cells and is at least as active as cisplatin on the MDA-MB-231 breast cancer cell line. In the in vivo toxicity estimation of complex 3 no signs of common toxicity were observed. Conclusion: The Pt(II)-bidentate complex 3 exhibited significant cytotoxic potential equaling or surpassing that of the reference drug cisplatin in all the tested tumor models. Negligible anticancer activity on the screened tumor types has been shown by the ligand L and its Pt(II) and Pt(IV) complexes 1 and 2, respectively. Our study on the acute toxicity of the most active complex 3 proved it to be non-toxic in mice models.

APA, Harvard, Vancouver, ISO, and other styles

6

Markman, Maurie. "Toxicities of the platinum antineoplastic agents." Expert Opinion on Drug Safety 2, no. 6 (November 2003): 597–607. http://dx.doi.org/10.1517/14740338.2.6.597.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Makrilia, Nektaria, Ekaterini Syrigou, Ioannis Kaklamanos, Leonidas Manolopoulos, and Muhammad Wasif Saif. "Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review." Metal-Based Drugs 2010 (September 20, 2010): 1–11. http://dx.doi.org/10.1155/2010/207084.

Full text

Abstract:

Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the first-line setting of numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last decade has led to a significant increase in the incidence of hypersensitivity reactions, which are defined as unforeseen reactions whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, flushing, abdominal cramping, itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications can prove fatal. Multiple pathogenetic mechanisms have been suggested. Hypersensitivity usually appears after multiple infusions, suggesting type I allergic reactions; however, other types of hypersensitivity also seem to be implicated. Several management options are available to treating physicians: discontinuation of chemotherapy, premedication, prolonging of infusion duration, desensitization protocols, and replacement with a different platinum compound after performing skin tests that rule out cross-reactions among platinum agents.

APA, Harvard, Vancouver, ISO, and other styles

8

Fanelli, Mirco, Mauro Formica, Vieri Fusi, Luca Giorgi, Mauro Micheloni, and Paola Paoli. "New trends in platinum and palladium complexes as antineoplastic agents." Coordination Chemistry Reviews 310 (March 2016): 41–79. http://dx.doi.org/10.1016/j.ccr.2015.11.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bakhonsky, Vladyslav V., Aleksander A. Pashenko, Jonathan Becker, Heike Hausmann, Huub J. M. De Groot, Herman S. Overkleeft, Andrey A. Fokin, and Peter R. Schreiner. "Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(ii) complexes." Dalton Transactions 49, no. 40 (2020): 14009–16. http://dx.doi.org/10.1039/d0dt02391d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (February 1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text

Abstract:

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information is submitted to the FDA for their review and approval for marketing. Prior to that approval, the FDA may approve broader distribution of the drug for specific indications under a Treatment Investigational New Drug (IND) or the National Cancer Institute's (NCI) group C mechanism. Pharmacists can play a unique role during development of the Treatment IND by contributing to design of the protocol and screening patient qualifications. The investigator of the clinical trial has responsibility for the conduct of the clinical trial and must comply with FDA regulations and sponsor policies. This is a US government work. There are no restrictions on its use.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Platinum group. Antineoplastic agents"

1

Flynn, Allison. "Transition metals as anti-tumoral agents : some structure-function relationships of the platinum group metals /." Master's thesis, This resource online, 1994. http://scholar.lib.vt.edu/theses/available/etd-03022010-020016/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dewa, Shaliza Zaini. "Novel 3,3-dialkyldiaziridine platinum and palladium complexes." Thesis, University of Sussex, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Oosthuizen, Lukas Marthinus. "New platinum coordination compounds : their synthesis, characterization and anticancer application." Thesis, Nelson Mandela Metropolitan University, 2009. http://hdl.handle.net/10948/d1018795.

Full text

Abstract:

The aim of this thesis was to investigate the properties of novel platinum compounds with possible potential as anticancer agents, and to determine how their behaviour could lead to a better understanding of the chemistry involved. The final criteria were improvement of their anticancer behaviour. Since many questions are still unanswered as to the role of sulfur in anticancer action, studies were undertaken to synthesize novel platinum(II) complexes having non-leaving groups consisting of a combination of an aromatic nitrogen and thioetherial sulfur capable of forming a five membered ring upon coordination. The structural unit was 1-methyl-2-methylthioalkyl/aryl. Numerous complexes formed by these ligands each having chloro, bromo, iodo and oxalato leaving groups were then fully characterized. The results obtained by the various synthetic methods were compared and explained in terms of the chemistry involved. The role of the sulfur donor was indicated in both the halo- and oxalato-complexes and proved to be strongly influenced by the nature of the leaving groups. Their differences are reflected in their anticancer behaviour. The study was extended to mononitroplatinum(IV) complexes, in view of the kinetically stable platinum(IV) compounds and advantages related to this. A specific mononitroplatinum(IV) complex which proved to have good anticancer and STAT 3 properties could according to the literature not be synthesized successfully in a good yield and a high degree of purity. The results of extensive studies showed that the main problem centred around the simultaneous reactions in equilibrium during the synthesis. A number of these species formed as a result of side reactions could be identified and their close separation factors indicated chromatographically. The mechanism of these reactions and the unstable intermediate species involved could be rationalized and compared to analogues in the literature. All the complexes studied were characterized by spectral and thermal methods both in solution as well as the solid state. Their anticancer behaviour towards three anticancer cell lines (Hela, MCF 7, Ht 29) were determined and acted as a guide towards possible structural modifications for their improved capability. Three crystal structures of platinum(II) complexes were determined. The extent of the ionization of the platinum(II) complexes as well the redox potentials (Pt(II) / Pt(IV)) of the platinum(IV) complexes were particularly important factors pertaining to their anticancer action.

APA, Harvard, Vancouver, ISO, and other styles

4

Jaganath, Yatish. "Advances in platinum-amine chemotherapeutic agents : their chemistry and applicationc." Thesis, Nelson Mandela Metropolitan University, 2009. http://hdl.handle.net/10948/d1021222.

Full text

Abstract:

The research conducted in this study focussed on advancing the knowledge database of diamineplatinum complexes on two frontiers: 1) the development of novel anticancer complexes, and 2) improvements in their synthetic chemistry. Novel square-planar dichloro and oxalato platinum(II) complexes were synthesized as potential anticancer agents in accordance with a comprehensive set of factors identified as being significant in optimizing such action. The nonleaving ligands consisted of asymmetric chelating chiral diamines of the form 1- (1-R-imidazol-2yl)(R')methanamine (R representing methyl, butyl and R' methyl, phenyl). The complexes were characterized by a host of spectral, thermal and crystallographic techniques. In addition, the stabilities of the complexes were monitored in aqueous and saline solutions. Cytotoxicity screening on three cultured cancer cell lines (MCF-7, HeLa and HT29) indicated the compounds, present as their respective racemates, to have rather modest activities relative to cisplatin; with complexes having the smallest substituents, R,R' = methyl, being most active. In recognition of the limitations of traditional silver-based syntheses of oxalatoplatinum(II) complexes, innovative non-silver methods were developed using the well known cancer drug, oxaliplatin, (trans-R,R-1,2- diaminocyclohexane)oxalatoplatinum(II), as a prototype. These involved direct ligand exchange reactions of the dichloro precursor, (trans-R,R-1,2- diaminocyclohexane)dichloroplatinum(II), with tetrabutylammonium oxalate in essentially non-aqueous solvents. A 90:10 mixture of isoamyl alcohol (3-methyl- 1-butanol):water, proved to be a promising solvent, enabling the recovery of pure oxaliplatin (~98 percent) after 9 hours at 88 °C in yields of up to 86 percent. In light of the perceived unique mode of anticancer action available to mononitroplatinum(IV) complexes (i.e. their STAT3-binding potential), octahedral diamineoxalatoplatinum(IV) complexes containing axially-coordinated nitro and halo co-ligands were synthesized and extensively characterized. Electrochemical studies revealed trends in reduction potential which could be correlated to structural / chemical traits of the coordinated diamine and axial ligands. The similarities of the determined cytotoxicities of the platinum(IV) compounds and their respective platinum(II) analogues, implicated reduction as a means of activation of the platinum(IV) complexes.

APA, Harvard, Vancouver, ISO, and other styles

5

McCandless, Stewart Grant. "The synthesis of some novel 1,2,3-benzotriazine-platinum complexes with potential antineoplastic activity." Thesis, Heriot-Watt University, 1988. http://hdl.handle.net/10399/999.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Wang, Xinghao, and 王星昊. "Platinum on the road: the activation and transport of novel platinum anticancer drugs by the extracellulardomain of human copper transporter I (HCTR1)." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48199205.

Full text

Abstract:

Platinum-based anticancer drugs such as cisplatin, carboplatin and nedaplatin have been widely used in the chemotherapy of a variety of solid tumours for several decades. However, the development of both inherent and acquired resistance has greatly limited the efficacy of all of these drugs. Several mechanisms were proposed to explain the cellular resistance to these platinum drugs, including decreased drug accumulation. Previously, it was suggested that cisplatin enters cells via passive diffusion, followed by intracellular hydrolysis and activation prior to targeting DNA. However, recent in vivo and in vitro studies confirmed that transporters and carriers involved in copper homeostasis play important roles on the transport as well as cellular resistance to the platinum drugs. CTR1, a major plasma-membrane transporter involved in intracellular copper(I) homeostasis, was found to facilitate the uptake of several platinum drugs although the molecular mechanism remains unclear. The extracellular N-terminal domain of human CTR1 (hCTR1) with two methionine(Met)-rich and two histidine(His)-rich motifs has been proved to be essential for the uptake of both copper and platinum drugs by the transporter. In this thesis, the extracellular domain of hCTR1 (hCTR1_N, residues 1-55) was overexpressed and the role of the Met- and His-rich motifs on cisplatin binding was examined by either mutagenesis or chemical modification. Cisplatin was found to directly and rapidly bind to the Met residues of hCTR1_N by the formation of monofunctional cisplatin-thioether adducts. The kinetics of the binding process was found to correlate with the number of Met residues, indicating that all Met residues are exposed to solvents and capable for cisplatin binding. Such a non-sequence-specific binding may increase the likelihood of capturing the anticancer drug in extracellular fluid by the N-terminus of hCTR1. The effect of hCTR_N on the binding and activation of second-generation platinum anticancer drugs, e.g. carboplatin and nedaplatin, were subsequently investigated. hCTR1_N was found to significantly facilitate the activation of these platinum drugs by the formation of ring-opened monofunctional Pt-thioether species through Met residues. Although the activities of platinum drugs against hCTR1_N are significantly different, their monofunctional protein-bound species demonstrated great similarity in both structure and kinetic aspects, suggesting the uptake of these platinum drugs by hCTR1 might follow the same mechanism. The formation of active ring-opened species of carboplatin and nedaplatin by chloride/bicarbonate was observed, indicating these nucleophiles may play a critical role in the pre-activation of the drugs prior to their reaching cellular targets. Pt-thioether species were proposed as intermediates for the platination of other biomolecules. The monofunctional cisplatin adduct of hCTR1_N was proved to further transfer its active platinum species to either cysteine- or guaninecontaining biomolecules which mimic the C-ternimus of hCTR1 and DNA. Methionine residues of hCTR1 may therefore serve as key residues for the activation and transport of platinum anticancer drugs in the form of monofunctional Pt-thioether species through the pole of trimeric hCTR1 and eventually to their final target – DNA.
published_or_final_version
Chemistry
Doctoral
Doctor of Philosophy

APA, Harvard, Vancouver, ISO, and other styles

7

Yachnin, Jeffrey R. "Chemical, pharmacokinetic and biological aspects of platinum-based drugs /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-221-7/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Phelps, Jennifer Suzanne 1960. "CISPLATIN NEPHROTOXICITY: IN VITRO STUDIES (KIDNEY, TOXICOLOGY, PLATINUM)." Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/291243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bouwer, Yolanda. "Novel aspects of platinum-amine coordination compounds: their chemistry and anticancer application." Thesis, Nelson Mandela Metropolitan University, 2008. http://hdl.handle.net/10948/d1021052.

Full text

Abstract:

The aim in this thesis, was to synthesize novel platinum coordination compounds, in order to develop compounds with improved anticancer action which could lead to an improved understanding of the mechanism by which they operate and at the same time, improve synthetic methods for their products. The initial work included the development of a novel synthetic method for 1R,2R-diaminocyclohexaneoxalato-platinum(II) (oxaliplatin), by using an essentially non-aqueous solvent medium and direct ligand exchange at elevated temperatures. This was done by a study of the kinetics of the reaction in a variety of conditions; such as relative reagent concentrations and ratios as well as solvent mixtures. An effective method was developed which could be applied industrially. An international patent was taken out on this method. Various amine complexes of platinum(II) were synthesized using chloro, bromo and oxalato groups as leaving groups. The non-leaving groups were selected having certain specific characteristics in mind. Novel mononitroplatinum(IV) complexes were synthesized, mostly with oxalato leaving groups. One of these in particular, had excellent anticancer behaviour. Another trichloromononitro complex was also synthesized with very good anticancer properties. Two international patents were filed for the latter two compounds. As far as possible, all compounds were studied by spectrometric, chromatographic and thermal methods. They were also tested against 3 cancer cell lines namely cervical (Hela), Colon (HT29) and Breast (MCF7) cancer cells.

APA, Harvard, Vancouver, ISO, and other styles

10

Myburgh, Jolanda. "Synthesis and characterization of novel platinum complexes : their anticancer behaviour." Thesis, Nelson Mandela Metropolitan University, 2009. http://hdl.handle.net/10948/d1018621.

Full text

Abstract:

In this dissertation novel non-leaving groups were employed to synthesize platinum complexes which can contribute to the understanding or improvement of anticancer action. These complexes basically consist of (NS)-chelate and amineplatinum complexes. Bidentate (NS)-donor ligands were used as non-leaving ligands in the syntheses of platinum(II) complexes with iodide, chloride, bromide and oxalate anions as leaving groups. These complexes were synthesized and studied since many questions regarding the interaction of sulfur donors and platinum still exists. These relate to thermodynamic and kinetic factors and their influence on anticancer action. In this dissertation the properties of novel platinum(II) complexes of a bidentate ligand having an aromatic nitrogen-donor atom in combination with a thioethereal sulfur atom capable of forming a five membered ring with platinum(II) were studied. The general structure of the (NS) -ligands used were N-alkyl-2-methylthioalkyl imidazole. Alkyl groups used were methyl, ethyl and propyl. Although amine complexes of platinum have been extensively studied there are some new aspects of these that are worthwhile investigating. In this dissertation amines having planar attachments which will be at an angle with the coordination plane viz. benzylamine and amines having cyclic aliphatic groups namely cyclopropyl and cyclohexyl were investigated. Some of the (NS) - and amineplatinum(II) complexes were oxidised to their mononitroplatinum(IV) analogues . The motivation for the synthesis of these complexes was the greater kinetic stability of platinum(IV) and recent research has shown that a specific type of platinum(IV) compound shows suitable properties as an anticancer agent. These complexes were characterised by a variety of spectral means (IR, NMR, mass spectroscopy) as well as elemental analysis, solubility determinations, thermal analysis (TGA), ionization studies and finally their anticancer behaviour towards three different cell lines(Hela, MCF 7, Ht29) and in this process they were compared to the behaviour of cisplatin as a reference. A few have shown promising anticancer behaviour.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Platinum group. Antineoplastic agents"

1

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (6th 1991 San Diego, Calif.). Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

M, Pinedo H., and Schornagel J. H, eds. Platinum and other metal coordination compounds in cancer chemotherapy 2. New York: Plenum Press, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Meeting, National Cancer Institute (U S. ). Cancer Therapy Evaluation Program Investigational Drug Branch Phase I. Working Group. Minutes of the Phase I Working Group and the Biochemical Modulators Advisory Group, November 14-15, 1985. Bethesda, Md: Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

National Cancer Institute (U.S.). Cancer Therapy Evaluation Program. Investigational Drug Branch. Phase I Working Group. Meeting. Minutes of the Phase I Working Group and the Biochemical Modulators Advisory Group, November 17-18, 1986. Bethesda, Md: Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Meeting, National Cancer Institute (U S. ). Cancer Therapy Evaluation Program Investigational Drug Branch Phase I. Working Group. Minutes of the Phase I Working Group and the Biochemical Modulators Advisory Group, July 8-9, 1986. Bethesda, Md: Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

International, Congress on Neo-Adjuvant Chemotherapy (2nd 1987 Paris France). Paraplatine: Carboplatine: symposium satellite du deuxième congrès international sur la chimiothérapie néo-adjuvante Paris, 20 frévier 1988. Paris: Libbey Eurotext, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Marino, Nicolini, ed. Platinum and other metal coordination compounds in cancer chemotherapy: Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Abano Padua, Italy, June 29-July 2, 1987. Boston: Nijhoff, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

International Symposium on Platinum Coodination Compounds in Cancer Chemotherapy (10th 2007 Verona, Italy). Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. New York: Humana Press, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

International Symposium on Platinum Coodination Compounds in Cancer Chemotherapy (10th 2007 Verona, Italy). Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. New York: Humana Press, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sciences), Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity (1986 Pontifical Academy of. Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity, October 21-25, 1986. Città del Vaticano: Pontificia Academia Scientiarvm ; Schenectady, N.Y. : Adenine Press [distributor], 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Platinum group. Antineoplastic agents"

1

Bruder, Beatrice, Clare L. S. Wiseman, and Fathi Zereini. "Solubility of Emitted Platinum Group Elements (Pt, Pd and Rh) in Airborne Particulate Matter (PM10) in the Presence of Organic Complexing Agents." In Environmental Science and Engineering, 265–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44559-4_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Taber, Douglass F. "The Krische Synthesis of Bryostatin 7." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0090.

Full text

Abstract:

The bryostatins, as exemplified by bryostatin 75, are an exciting class of natural products. In addition to being effective antineoplastic agents, they show activity against Alzheimer’s disease. The central ring-forming step in the synthesis of 5 reported (J. Am. Chem. Soc. 2011, 133, 13876) by Michael J. Krische of the University of Texas, Austin is the triply convergent coupling of the chirons 1 and 2 with the linchpin reagent 3. The preparation of 1 and of 2 showcases the hydrogen transfer strategy for carbon–carbon bond construction developed by the Krische group. The synthesis of 2 began with the previously described double coupling of the simple starting materials 6 and 7. The product diol 8 had >99% ee. Ozonolysis of 8 was followed by a reductive coupling with the allene, which installed the gem dimethyl substituents of 2, and also the third oxygenated stereogenic center. The preparation of 1 proceeded from the aldehyde 10, prepared by Sharpless asymmetric dihydroxylation of 3-pentenenitrile. The chelate-controlled addition of propargyl zinc 11 led to the alkyne 12. Reductive coupling of the alkyne of 12 with the aldehyde of 13, again following a Krische procedure, delivered 1. The triply convergent Keck-Yu condensation of 1 with 3, and then with 2, gave, after some manipulation, the desired tetrahydropyran 4. Selective hydrolysis of the methyl ester in the presence of the acetates followed by selective silylation of two of the three secondary hydroxyls gave a suitable substrate for Yamaguchi cyclization to give 14. Selective oxidative cleavage of two of the three alkenes then gave an intermediate keto aldehyde that was carried on to bryostatin 7 5 following known procedures. The key to the synthesis of the complex bryostatin 7 5 was the ready supply of the chirons 1 and 2, prepared by the simple but powerful enantioselective reductive couplings developed by the Krische group. These couplings will have many other applications in target-directed synthesis.

APA, Harvard, Vancouver, ISO, and other styles

3

Taber, Douglass F. "Stereoselective C–O Ring Construction: The Keck Synthesis of Bryostatin I." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0046.

Full text

Abstract:

Vladimir Gevorgyan of the University of Illinois, Chicago homologated (Angew. Chem. Int. Ed. 2011, 50, 2808) the ketone 1 to the epoxide 2 using cyanogen bromide. Manabu Abe of Hiroshima University optimized (J. Am. Chem. Soc. 2011, 133, 2592) the diastereoselectivity of the Paternò-Büchi addition of benzophenone 4 to the secondary allylic alcohol 3 to give 5. Debaraj Mukherjee of the Indian Institute of Integrative Medicine constructed (Org. Lett. 2011, 13, 576) the lactone 7 by adding acetate to 6, with remarkable regioselectivity and diastereoselectivity. Tristan H. Lambert of Columbia University employed (Org. Lett. 2011, 13, 740) cyclopropenium activation to cyclize the diol 8 to 9. Brian L. Pagenkopf of the University of Western Ontario designed (Org. Lett. 2011, 13, 572) a Co catalyst for the diastereoselective oxidative cyclization of 11 to 12. Goverdhan Mehta of the Indian Institute of Science, Bangalore, found (Tetrahedron Lett. 2011, 52, 1749) that the Z-diene 13 cyclized efficiently to give the cyclic ether 14. Fabien Gagosz of the Ecole Polytechnique found (J. Am. Chem. Soc. 2011, 133, 7696) that the protonated complex derived from the allene 15 abstracted a hydride from the distal benzyl group, leading to cyclization to 16. Haruhiko Fuwa of Tohoku University found (Org. Lett. 2011, 13, 1820) that the unsaturated thioester 17 cyclized under gentle acid catalysis. Unsaturated esters (not illustrated) can be cyclized under alkaline conditions (Tetrahedron Lett. 2011, 52, 1372). Malcolm D. McLeod of the Australian National University established (J. Org. Chem. 2011, 76, 1992) a combination of Escherichia coli-derived enzyme and an α-d-glucuronyl fluoride donor for converting an alcohol 19 to the corresponding glucuronide metabolite 20. En route to an improved synthesis of the schweinfurthins, potent antineoplastic agents, David F. Wiemer of the University of Iowa devised (J. Org. Chem. 2011, 76, 909) the cyclization/ benzyloxymethyl transfer cascade that transformed 21 into 22. The synthesis and biological activity of the bryostatins is developing into one of the great success stories of natural products chemistry. A key step in the total synthesis of bryostatin 1 25 designed (J. Am. Chem. Soc. 2011, 133, 744) by Gary E. Keck of the University of Utah was the Rainier cyclization of 23 to 24.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Platinum group. Antineoplastic agents"

1

Nakka, Thejeswar, Prasanth Ganesan, Luxitaa Goenka, Biswajit Dubashi, Smita Kayal, Latha Chaturvedula, Dasari Papa, Prasanth Penumadu, Narendran Krishnamoorthy, and Divya B. Thumaty. "Epithelial Ovarian Cancer: Real-World Outcomes." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735369.

Full text

Abstract:

Abstract Introduction Ovarian cancer is the third most common cancer and the second most common cause of death among gynecological cancers in Indian women. Ovarian cancer is heterogeneous, among them, epithelial ovarian cancer (EOC) is the most common. Primary cytoreductive surgery along with six to eight cycles of a combination of platinum and taxanes chemotherapy is the cornerstone of first-line treatment in EOC. This study was done to find clinicopathological factors affecting survival outcomes with first-line therapy in EOC in a real-world setting. Objectives This study was aimed to find factors affecting progression-free survival (PFS) and overall survival (OS) with first-line treatment in EOC. Materials and Methods We conducted a single-center retrospective study. We screened all the patients diagnosed with ovarian cancer from January 2015 till December 2019. We locked data in August 2019. Eligible patients were histologically confirmed EOC who underwent primary cytoreduction or received more than or equal to two cycles of chemotherapy or both. Patients who had received first-line treatment at another hospital were excluded. Results Patients demographics and clinical characteristics: between January 5, 2015 to August 31, 2019, 435 patients with a diagnosis of ovarian malignancy were registered at our center. Among them, 406 (82%) had EOC, 290 (64%) newly diagnosed, and fulfilling eligibility criteria were included in the final analysis. The median age of the cohort was 53 years (range: 21–89 years) and 157 patients (54%) were >50 years of age (the Eastern Oncology Cooperative Group Performance status was ≥ 2 in 124 patients [43%]; median duration of symptoms was 3 months; and stage III/IV: 240 [83%]). Grading of the tumor was available in 240 patients of which 219 (91%) were of high grade. Subtyping was available in 272 patients (94%) of which the serous subtype was the most common constituting 228 patients (79%).Treatment Most patients received chemotherapy (n = 283 [98%]) as the first modality of treatment (neoadjuvant/adjuvant and palliative). As neoadjuvant (NACT) in 130 patients (45%) and as adjuvant following surgery in 81 patients (29%). The most common chemotherapy regimen was a combination of carboplatin and paclitaxel in 256 patients (88%). Among 290 patients 218 (75%) underwent cytoreductive surgery. Among them, optimal cytoreduction was achieved in 108 patients (52%). Optimal cytoreduction rate (OCR) with upfront surgery and after NACT was 44 and 53%, respectively (Chi-square test: 0.86; p = 0.35).Survival The median follow-up of the study was 17 months (range: 10–28 months) and it was 20 months (range: 12–35 months) for patients who were alive. At last, follow-up, 149 patients (51%) had progressed and 109 (38%) died. The estimated median PFS and OS were 19 months (95% CI: 16.1–21.0) and 39 months (95% CI: 29.0–48.8), respectively. On multivariate analysis, primary surgery (HR: 0.1, 95% CI: 0.06–0.21; p-value: <0.001) and early-stage disease (HR: 0.2, 95% CI: 0.1–0.6; p-value 0.04) were associated with superior PFS and primary surgery (HR: 0.1, 95% CI: 0.09–0.2; p-value: <0.001) was associated with superior OS. Conclusion Primary surgery (upfront or interval) was associated with improved survival. Newer agents like bevacizumab, poly-ADP (adenosine diphosphate)-ribose polymerase inhibitors and HIPEC should be incorporated precisely into first line of therapy to improve outcomes.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!